Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2025
Does the use of pulsed-xenon ultraviolet light reduce the risk of healthcare-associated infections?: An updated systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Lejuan, Yan Chungen, Huang Yan, Lv Jvmei, Liu Siyan
Аннотация
OBJECTIVE: The present review was conducted to assess the ability of the pulsed-xenon ultra-violet system (PX-UVL) to reduce healthcare-associated infections (HAI).
METHODS: All types of studies available on PubMed, Embase, Scopus, and Web of Science databases assessing the risk of any HAI with the use of PX-UVL and published up to 25 February 2025 were included. Data on C. difficile infection (CDI), Methicillin-resistant Staphylococcus aureus (MRSA) infection, Vancomycin-resistant enterococci (VRE) infections, and Acinetobacter baumannii infections (ABI) was pooled.
RESULTS: Fourteen studies were included. Most studies had a pre-post study design while two were controlled trials. Meta-analysis showed a statistically significant reduction in the risk of CDI with PX-UVL (RR: 0.76 95 % CI: 0.59, 0.97 I2 = 72 %). However, results were significant only for pre-post studies (RR: 0.75 95 % CI: 0.57, 0.98 I2 = 73 %) but not for controlled trials (RR: 0.70 95 % CI: 0.25, 1.96 I2 = 72 %). The results were also not stable on sensitivity analysis. Meta-analysis also showed a tendency of reduction of MRSA infections but the effect size was statistically non-significant (RR: 0.80 95 % CI: 0.62, 1.02 I2 = 65 %). Pooled analysis demonstrated no significant impact of PX-UVL in reducing the risk of VRE infections (RR: 0.83 95 % CI: 0.66, 1.04 I2 = 54 %) or ABI (RR: 0.64 95 % CI: 0.21, 1.90 I2 = 96 %). Subgroup analysis based on study design showed that the risk of VRE infection did not change in both pre-post studies and controlled trials.
CONCLUSIONS: Current evidence from variable study designs suggests that PX-UVL may have limited efficacy in reducing HAI. Further high-quality randomized controlled trials will provide quality evidence.
METHODS: All types of studies available on PubMed, Embase, Scopus, and Web of Science databases assessing the risk of any HAI with the use of PX-UVL and published up to 25 February 2025 were included. Data on C. difficile infection (CDI), Methicillin-resistant Staphylococcus aureus (MRSA) infection, Vancomycin-resistant enterococci (VRE) infections, and Acinetobacter baumannii infections (ABI) was pooled.
RESULTS: Fourteen studies were included. Most studies had a pre-post study design while two were controlled trials. Meta-analysis showed a statistically significant reduction in the risk of CDI with PX-UVL (RR: 0.76 95 % CI: 0.59, 0.97 I2 = 72 %). However, results were significant only for pre-post studies (RR: 0.75 95 % CI: 0.57, 0.98 I2 = 73 %) but not for controlled trials (RR: 0.70 95 % CI: 0.25, 1.96 I2 = 72 %). The results were also not stable on sensitivity analysis. Meta-analysis also showed a tendency of reduction of MRSA infections but the effect size was statistically non-significant (RR: 0.80 95 % CI: 0.62, 1.02 I2 = 65 %). Pooled analysis demonstrated no significant impact of PX-UVL in reducing the risk of VRE infections (RR: 0.83 95 % CI: 0.66, 1.04 I2 = 54 %) or ABI (RR: 0.64 95 % CI: 0.21, 1.90 I2 = 96 %). Subgroup analysis based on study design showed that the risk of VRE infection did not change in both pre-post studies and controlled trials.
CONCLUSIONS: Current evidence from variable study designs suggests that PX-UVL may have limited efficacy in reducing HAI. Further high-quality randomized controlled trials will provide quality evidence.